Autonomic Nervous System Drugs — MCQs

Autonomic Nervous System Drugs Indian Medical PG Practice Questions and MCQs

Question 471: Aggravation of myasthenia gravis is a feature of all the following drugs except?

A. Gentamicin
B. Neomycin
C. Edrophonium (Correct Answer)
D. Succinylcholine

Explanation: **Explanation:** The correct answer is **Edrophonium**. This question tests your understanding of drugs that interfere with neuromuscular transmission versus those that enhance it. **1. Why Edrophonium is correct:** Edrophonium is a short-acting **reversible acetylcholinesterase inhibitor**. By inhibiting the enzyme that breaks down acetylcholine (ACh) in the synaptic cleft, it increases the concentration of ACh available to bind to nicotinic receptors at the neuromuscular junction (NMJ). This **improves** muscle strength in Myasthenia Gravis (MG) patients. Historically, it was used in the **Tensilon Test** to diagnose MG. **2. Why the other options are wrong:** * **Gentamicin & Neomycin (Aminoglycosides):** These antibiotics are notorious for aggravating MG. They inhibit the pre-synaptic release of acetylcholine and reduce post-synaptic sensitivity to ACh. They are generally contraindicated or used with extreme caution in MG patients. * **Succinylcholine:** This is a depolarizing neuromuscular blocker. MG patients have a reduced number of functional nicotinic receptors; they are often resistant to succinylcholine initially, but it can lead to a prolonged Phase II block, causing unpredictable and potentially severe respiratory depression/aggravation of weakness. **Clinical Pearls for NEET-PG:** * **Drugs to avoid in MG:** Aminoglycosides, Quinolones, Beta-blockers, Lithium, Magnesium salts, and Procainamide. * **Tensilon Test:** Edrophonium is used to differentiate between a **Myasthenic Crisis** (improvement seen) and a **Cholinergic Crisis** (worsening seen due to depolarization block). * **Treatment of choice for MG:** Pyridostigmine (longer-acting cholinesterase inhibitor) is the first-line oral treatment.

Question 472: Organophosphates act by inhibiting the enzyme acetylcholinesterase. Which type of enzyme inhibitors are they?

A. Competitive and reversible
B. Non-competitive and irreversible
C. Uncompetitive and reversible
D. Competitive and irreversible (Correct Answer)

Explanation: ### Explanation **1. Why Option D is Correct:** Organophosphates (OPs) are **competitive** inhibitors because they bind to the active site (esteratic site) of the acetylcholinesterase (AChE) enzyme, competing with the natural substrate, acetylcholine. They are **irreversible** inhibitors because they form a stable covalent bond (phosphorylation) with the serine residue at the active site. Once this bond undergoes a process called **"aging"** (loss of an alkyl group), the enzyme-inhibitor complex becomes extremely stable and cannot be broken by oximes, leading to permanent inactivation of the enzyme. **2. Why Other Options are Incorrect:** * **Option A (Competitive and Reversible):** This describes drugs like **Edrophonium** (used in the Tensilon test) or carbamates like Neostigmine. These bind non-covalently or form a carbamylated complex that eventually dissociates. * **Option B (Non-competitive and Irreversible):** Non-competitive inhibitors bind to an allosteric site, not the active site. OPs specifically target the active esteratic site. * **Option C (Uncompetitive and Reversible):** Uncompetitive inhibitors bind only to the enzyme-substrate complex. This mechanism is rare in clinical pharmacology and does not apply to AChE inhibitors. **3. Clinical Pearls & High-Yield Facts for NEET-PG:** * **Mechanism of Toxicity:** Accumulation of acetylcholine leads to a "Cholinergic Crisis" (SLUDGE: Salivation, Lacrimation, Urination, Defecation, GI distress, Emesis). * **Management:** * **Atropine:** Specific physiological antidote (antagonizes muscarinic effects). * **Pralidoxime (2-PAM):** Enzyme reactivator. It must be administered **before "aging"** occurs to be effective. * **Diagnosis:** Measurement of **RBC Cholinesterase** levels is a more reliable indicator of chronic exposure than plasma cholinesterase. * **Common Examples:** Malathion, Parathion (insecticides), and Nerve Gases (Sarin, Soman).

Question 473: A drug is a tertiary amine while another drug is a quaternary ammonium compound. Which of the following statements is true regarding these drugs?

A. The tertiary amine is likely to be more potent than the quaternary ammonium compound.
B. The quaternary ammonium compound will produce CNS effects.
C. The quaternary ammonium compound will be completely metabolized in the body.
D. The tertiary amine will be more suitable to be used as a miotic. (Correct Answer)

Explanation: This question tests your understanding of the pharmacokinetic differences between **Tertiary Amines** and **Quaternary Ammonium compounds**, a high-yield concept in Autonomic Pharmacology. ### **Core Concept: Lipid Solubility vs. Ionization** * **Tertiary Amines (e.g., Physostigmine, Atropine):** These are uncharged, lipid-soluble molecules. They easily cross biological membranes, including the Blood-Brain Barrier (BBB) and the corneal epithelium of the eye. * **Quaternary Ammonium Compounds (e.g., Neostigmine, Ipratropium):** These are permanently charged (ionized) and water-soluble. They do not cross lipid membranes easily and have poor CNS penetration. ### **Why Option D is Correct** To act as a **miotic** (constricting the pupil), a drug applied topically to the eye must penetrate the lipid-rich corneal epithelium to reach the iris muscles. Because **tertiary amines** are lipid-soluble, they are absorbed much more effectively into the anterior chamber of the eye compared to quaternary compounds. ### **Analysis of Incorrect Options** * **Option A:** Potency is determined by receptor affinity and intrinsic activity, not merely by the amine structure. Many quaternary compounds (like Neostigmine) are highly potent at the NMJ. * **Option B:** Quaternary compounds are ionized and **cannot cross the Blood-Brain Barrier**. Therefore, they do not produce significant CNS effects. * **Option C:** Being quaternary does not dictate the metabolic pathway; many are excreted unchanged in the urine or hydrolyzed by plasma esterases. ### **High-Yield NEET-PG Pearls** * **Physostigmine (Tertiary)** is the drug of choice for Atropine poisoning because it crosses the BBB to reverse central anticholinergic symptoms. * **Neostigmine (Quaternary)** is preferred for Myasthenia Gravis because it targets peripheral receptors without causing unwanted CNS side effects. * **Mnemonic:** **T**ertiary = **T**raverses membranes (CNS/Eye); **Q**uaternary = **Q**uits (stays outside the CNS).

Question 474: Which precursor of adrenaline is responsible for renal vasodilation?

A. Dopamine (Correct Answer)
B. Adrenaline
C. Noradrenaline
D. Acetylcholine

Explanation: **Explanation:** The correct answer is **Dopamine**. **Why Dopamine is correct:** Dopamine is the immediate biochemical precursor of Noradrenaline and Adrenaline in the catecholamine synthesis pathway (Tyrosine → L-Dopa → Dopamine → Noradrenaline → Adrenaline). At low doses (0.5–2 µg/kg/min), dopamine acts on **D1 receptors** located in the renal, mesenteric, and coronary vascular beds. Activation of these receptors leads to **vasodilation**, increasing renal blood flow and the glomerular filtration rate (GFR). **Why the other options are incorrect:** * **Adrenaline:** While it is the final product of the pathway, it acts primarily on $\alpha$ and $\beta$ receptors. At therapeutic doses, it typically causes vasoconstriction in the skin and viscera ($\alpha_1$) and vasodilation in skeletal muscle ($\beta_2$), but it does not have a specific vasodilatory effect on renal vessels like dopamine. * **Noradrenaline:** This is a potent $\alpha_1$ and $\alpha_2$ agonist with some $\beta_1$ activity. It causes intense systemic vasoconstriction, which can actually reduce renal blood flow. * **Acetylcholine:** This is the primary neurotransmitter of the parasympathetic nervous system. While it can cause vasodilation via nitric oxide release, it is not a precursor to adrenaline. **High-Yield Clinical Pearls for NEET-PG:** * **Dose-Dependent Effects of Dopamine:** * **Low dose (D1):** Renal vasodilation ("Renal dose"). * **Medium dose ($\beta_1$):** Positive inotropic effect on the heart. * **High dose ($\alpha_1$):** Systemic vasoconstriction. * **Fenoldopam:** A selective D1 agonist used in hypertensive emergencies to maintain renal perfusion. * **Rate-limiting step:** Tyrosine hydroxylase is the rate-limiting enzyme in catecholamine synthesis.

Question 475: A patient complains of muscle weakness. This weakness is reversed on administration of neostigmine. What is the mechanism of action of neostigmine in this scenario?

A. It blocks the action of acetylcholine.
B. It interferes with the action of monoamine oxidase.
C. It interferes with the action of carbonic anhydrase.
D. It interferes with the action of acetylcholine esterase. (Correct Answer)

Explanation: ### Explanation **1. Why Option D is Correct:** Neostigmine is a **reversible anticholinesterase** agent. In conditions like Myasthenia Gravis, muscle weakness occurs due to a reduction in functional nicotinic acetylcholine receptors (Nm) at the neuromuscular junction. Neostigmine works by binding to and inhibiting the enzyme **Acetylcholinesterase (AChE)**. This enzyme is responsible for the degradation of Acetylcholine (ACh) into choline and acetate. By inhibiting AChE, neostigmine prevents the breakdown of ACh, leading to an increased concentration and prolonged duration of action of ACh at the synaptic cleft [1]. This allows more ACh to interact with the remaining receptors, thereby improving muscle strength. **2. Why Other Options are Incorrect:** * **Option A:** Blocking the action of ACh (like Atropine or Curare) would worsen muscle weakness, not reverse it. * **Option B:** Monoamine oxidase (MAO) inhibitors are used in psychiatry (depression) and Parkinson’s disease; they affect catecholamines (Dopamine, NE), not the neuromuscular junction. * **Option C:** Carbonic anhydrase inhibitors (like Acetazolamide) are used for glaucoma or altitude sickness and have no direct effect on cholinergic transmission. **3. Clinical Pearls for NEET-PG:** * **Structure:** Neostigmine is a **quaternary ammonium** compound; it is polar and **does not cross the blood-brain barrier (BBB)**. * **Clinical Uses:** Treatment of Myasthenia Gravis, reversal of non-depolarizing muscle relaxants (e.g., Vecuronium), and postoperative paralytic ileus/urinary retention. * **Side Effects:** Excessive muscarinic stimulation (miosis, bradycardia, salivation). These are often managed by co-administering **Atropine or Glycopyrrolate**. * **Diagnostic Test:** While Neostigmine is used for treatment, **Edrophonium** (Tensilon test) is the classic short-acting agent used for diagnosis.

Question 476: Nicotinic receptor sites include all of the following except?

A. Bronchial smooth muscle (Correct Answer)
B. Adrenal medulla
C. Skeletal muscle
D. Sympathetic ganglia

Explanation: ### Explanation The correct answer is **A. Bronchial smooth muscle**. Nicotinic receptors (N) are **ligand-gated ion channels** (ionotropic receptors), whereas Muscarinic receptors (M) are **G-protein coupled receptors** (metabotropic receptors). **1. Why Bronchial Smooth Muscle is the correct answer:** Bronchial smooth muscle contains **Muscarinic (M3)** receptors, not nicotinic receptors. Stimulation of M3 receptors by acetylcholine leads to bronchoconstriction and increased secretions. Nicotinic receptors are absent in the smooth muscles of the respiratory, gastrointestinal, and genitourinary tracts. **2. Analysis of Incorrect Options:** * **Adrenal Medulla (Option B):** It contains **$N_N$ (neuronal type)** nicotinic receptors. The adrenal medulla is embryologically a modified sympathetic ganglion; stimulation leads to the release of adrenaline and noradrenaline into the blood. * **Skeletal Muscle (Option C):** The neuromuscular junction (NMJ) contains **$N_M$ (muscle type)** nicotinic receptors. Activation causes depolarization of the motor endplate, leading to muscle contraction. * **Sympathetic Ganglia (Option D):** All autonomic ganglia (both sympathetic and parasympathetic) utilize **$N_N$** receptors for fast excitatory synaptic transmission. **3. NEET-PG High-Yield Pearls:** * **Nicotinic Receptor Types:** Remember $N_M$ (Neuromuscular junction) and $N_N$ (Autonomic ganglia, Adrenal medulla, and CNS). * **Mechanism:** Nicotinic receptors work via **Sodium ($Na^+$) and Potassium ($K^+$) influx**, causing rapid depolarization. * **Mnemonic for M3 locations:** **"B"** for **B**ronchoconstriction, **B**ladder contraction (detrusor), **B**owel movement (increased peristalsis), and **B**eaming (miosis/pupillary constriction). * **Clinical Correlation:** Neuromuscular blockers like Succinylcholine act on $N_M$ receptors, while Ganglionic blockers like Hexamethonium act on $N_N$ receptors.

Question 477: All of the following agents are used in glaucoma treatment, except?

A. Apraclonidine
B. Timolol
C. Pilocarpine
D. Metoprolol (Correct Answer)

Explanation: **Explanation:** The management of glaucoma focuses on reducing intraocular pressure (IOP) by either decreasing the production of aqueous humor or increasing its outflow. **Why Metoprolol is the correct answer:** While beta-blockers are a mainstay in glaucoma therapy, they must be **topical and non-selective** (like Timolol) or **$\beta_1$-selective topical** agents (like Betaxolol). **Metoprolol** is a systemic $\beta_1$-selective blocker primarily used for hypertension and cardiovascular conditions. It is not used in glaucoma because it does not have a dedicated ophthalmic formulation for effective IOP reduction and lacks the necessary pharmacokinetic profile for topical ocular use. **Analysis of Incorrect Options:** * **Apraclonidine:** An $\alpha_2$-adrenergic agonist. It reduces IOP by decreasing aqueous humor production and enhancing uveoscleral outflow. It is frequently used post-laser surgery to prevent IOP spikes. * **Timolol:** A non-selective beta-blocker ($\beta_1 + \beta_2$). It is the "gold standard" topical treatment that reduces IOP by decreasing aqueous humor synthesis from the ciliary body. * **Pilocarpine:** A direct-acting miotic (cholinergic agonist). It causes contraction of the ciliary muscle, which opens the trabecular meshwork and increases aqueous outflow. It is specifically used in acute angle-closure glaucoma. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** Prostaglandin analogues (e.g., Latanoprost) are currently the first-line treatment for Open-Angle Glaucoma due to high efficacy and once-daily dosing. * **Betaxolol:** The only $\beta_1$-selective blocker used topically; it is safer in patients with mild asthma compared to Timolol. * **Carbonic Anhydrase Inhibitors:** (e.g., Acetazolamide, Dorzolamide) decrease aqueous production by inhibiting $HCO_3^-$ secretion. * **Mnemonic for Aqueous Production Blockers:** "ABC" – **A**lpha-2 agonists, **B**eta-blockers, **C**arbonic anhydrase inhibitors.

Question 478: All of the following drugs are useful in detrusor instability except?

A. Solefenacin
B. Tolterodine
C. Flavoxate
D. Duloxetine (Correct Answer)

Explanation: The clinical condition described, **detrusor instability** (also known as overactive bladder or urge incontinence), is characterized by involuntary contractions of the detrusor muscle during the filling phase. This muscle is primarily under **parasympathetic (M3 receptor)** control [1]. Therefore, the mainstay of treatment is **Antimuscarinic drugs**, which promote bladder relaxation. **Why Duloxetine is the Correct Answer:** * **Mechanism:** Duloxetine is a **Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)**. It works by increasing the tone of the external urethral sphincter via Pudendal nerve stimulation (Onuf’s nucleus). * **Clinical Use:** It is indicated for **Stress Urinary Incontinence (SUI)**—leakage during coughing or sneezing—rather than detrusor instability (urge incontinence). It does not directly relax the detrusor muscle. **Analysis of Incorrect Options:** * **Solifenacin & Tolterodine:** These are competitive **M3-selective antagonists** [2]. They are the first-line pharmacological treatments for detrusor instability as they reduce involuntary bladder contractions and increase bladder capacity [1]. * **Flavoxate:** This is a papaverine-like drug with direct **smooth muscle relaxant** properties and weak anticholinergic activity [1]. It is used to symptomatic relief of urinary spasms/urgency. **High-Yield NEET-PG Pearls:** 1. **Mirabegron:** A **$\beta_3$-agonist** used for overactive bladder; it relaxes the detrusor by mimicking sympathetic activity. 2. **Oxybutynin:** Often considered the "gold standard" antimuscarinic but has high side effects (dry mouth) due to lack of M3 selectivity [2]. 3. **Darifenacin/Solifenacin:** Preferred for their high M3 selectivity, leading to fewer systemic side effects [1]. 4. **Drug of Choice for Nocturnal Enuresis:** Desmopressin (DOC); Imipramine (historically used).

Question 479: Tiotropium is contraindicated in:

A. Bronchial asthma
B. Hypertension
C. Urinary retention (Correct Answer)
D. Peptic ulcer disease

Explanation: **Explanation:** **Tiotropium** is a long-acting muscarinic antagonist (LAMA) that works by blocking M3 receptors [3]. While it is primarily administered via inhalation for respiratory conditions, systemic absorption can occur, leading to typical anticholinergic side effects. **Why Urinary Retention is the Correct Answer:** The bladder's detrusor muscle is primarily under the control of **M3 receptors**, which mediate contraction to facilitate voiding. Antimuscarinic drugs like Tiotropium cause relaxation of the detrusor muscle and contraction of the urethral sphincter. In patients with pre-existing urinary outflow obstruction (e.g., Benign Prostatic Hyperplasia), this can precipitate **acute urinary retention** [2], [4]. Therefore, it is contraindicated or must be used with extreme caution in such patients. **Analysis of Incorrect Options:** * **A. Bronchial Asthma:** Tiotropium is actually an **indication** for asthma (especially as an add-on therapy in Step 4/5 management) due to its potent bronchodilatory effects [1]. * **B. Hypertension:** Unlike sympathomimetics (e.g., Salbutamol), anticholinergics do not significantly elevate blood pressure. Hypertension is not a contraindication. * **D. Peptic Ulcer Disease:** Anticholinergics reduce gastric acid secretion (via M1 blockade). While not a primary treatment today, they certainly do not worsen ulcers [2]. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Tiotropium is "kinetic selective" for M3 receptors because it dissociates very slowly from M3 compared to M2 receptors, providing 24-hour bronchodilation [3]. * **Other Contraindications:** Use with caution in **Narrow-angle Glaucoma** (can increase intraocular pressure) [2]. * **Comparison:** Unlike Ipratropium (SAMA), which is short-acting and non-selective, Tiotropium is preferred for maintenance therapy in COPD [4].

Question 480: Norepinephrine action at the synaptic cleft is terminated by which mechanism?

A. Metabolism by COMT
B. Metabolism by MAO
C. Reuptake (Correct Answer)
D. Metabolism by acetylcholinesterase

Explanation: **Explanation:** The termination of Norepinephrine (NE) action at the synaptic cleft is primarily achieved through **Reuptake (Uptake-1)**. 1. **Why Reuptake is correct:** Approximately **75-90%** of the norepinephrine released into the synaptic cleft is rapidly removed by a high-affinity sodium-dependent transporter called the **Norepinephrine Transporter (NET)**. This process, known as **Uptake-1**, transports NE back into the presynaptic neuron. Once inside, it is either sequestered into vesicles for reuse or metabolized. This is the fastest and most significant mechanism for terminating its physiological effect. 2. **Why other options are incorrect:** * **Metabolism by COMT & MAO:** While Catechol-O-methyltransferase (COMT) and Monoamine oxidase (MAO) are responsible for the *metabolism* of catecholamines, they do not terminate the immediate synaptic action. COMT primarily handles circulating catecholamines in the liver and kidneys, while MAO is an intracellular enzyme located on the outer mitochondrial membrane. * **Metabolism by Acetylcholinesterase:** This enzyme is specific to the termination of **Acetylcholine** at cholinergic synapses (e.g., neuromuscular junctions) and has no role in adrenergic signaling. **High-Yield Clinical Pearls for NEET-PG:** * **Uptake-1 (Neuronal):** Inhibited by **Cocaine** and **Tricyclic Antidepressants (TCAs)**, leading to increased NE levels in the cleft (sympathomimetic effect). * **Uptake-2 (Extraneuronal):** A lower-affinity process where NE is taken up by non-neuronal cells (smooth muscle/endothelium); it is inhibited by corticosteroids. * **VMAT-2:** The transporter that pumps NE into storage vesicles; it is inhibited by **Reserpine**. * **Metabolite:** The major end-product of NE/Epinephrine metabolism excreted in urine is **VMA (Vanillylmandellic acid)**, which is a diagnostic marker for Pheochromocytoma.

Practice by Chapter

Cholinergic Agonists

Practice Questions

Cholinergic Antagonists

Practice Questions

Adrenergic Agonists

Practice Questions

Adrenergic Antagonists

Practice Questions

Ganglionic Agents

Practice Questions

Neuromuscular Blocking Agents

Practice Questions

Autonomic Drugs in Ophthalmology

Practice Questions

Autonomic Drugs in Cardiovascular Disease

Practice Questions

Autonomic Drugs in Respiratory Disease

Practice Questions

Autonomic Drugs in Urological Disorders

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free